SAVING LIVES
WITH AI AND
SPECIALIZED MRI
PROSTATID™
01 / ADVANCED
ProstatID™ is a software interface for post-processing MRI using cloud based computing, physician workstation integration, and AI image interpretation to provide highly accurate prostate cancer diagnostics.
02 / ACCURATE
ProstatID™ eliminates the visualization limitations of physicians using complex wholistic learning algorithms improving physician confidence and accuracy for precision diagnostics and cancer targeting for follow-up exams.
03 / ACCESSIBLE
ProstatID™ facilitates low cost prostate cancer screening by using affordable technology,
delivering significant patient throughput improvements, and can lower physician and care-provider liability insurance premiums.
MEET BOT IMAGE
OUR STORY
Bot Image™, Inc is a medical imaging software company that utilizes artificial intelligence technology for magnetic resonance imaging interpretation. Bot Image was incubated at ScanMed®, LLC, an established medical device company specializing in MRI hardware, prostate cancer detection, and COPD functional lung imaging with the intent of bringing highly accurate MRI interpretation software to physicians.
OUR TECHNOLOGY
Bot Image’s software interprets multi-parametric and bi-parametric MRI using random forest with instance weight and MR segmentation by deep learning with holistically-nested networks. Our first product, ProstatID™ was trained from thousands of proprietary MR image sets, radiologist interpretations, segmented prostate gland image sets, pathology laboratory results, correlation data, and first-pass AI interpretations to aid in the early diagnosis of prostate cancer.
OUR VISION
Bot Image, Inc will bring prostate cancer early detection with MRI and AI to the forefront of medicine with ProstatID™. Our highly advanced, non-invasive technology shows promise of delivering high 90th percentile sensitivity in detection, as well as, specificity (accuracy) with the near elimination of false positives and false negatives. Once refined, we will then utilize the same baseline AI algorithms to address the early diagnosis of other cancers and COPD.
LEARN MORE
